Question for people smarter than me: On a scale of 1-10, with
1 being research just started and
10 being validation/confirmation completed and actual sales started
where do we think BD1 sit in terms of being de-risked for the cancer diagnostic test?
For example are we a 6, moving to an 8 if the validation of Luminex platform comes back okay?
future MCap vs peers, page-5
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
49.5¢ |
Change
0.020(4.21%) |
Mkt cap ! $55.20M | |||
| Open | High | Low | Value | Volume |
| 47.5¢ | 49.5¢ | 47.0¢ | $36.17K | 75.27K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 16000 | 48.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 50.0¢ | 8947 | 1 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| IIQ (ASX) Chart |